Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505801 | 0.79 | KCNN4 (0.47) | KMT2AMAPTKCNN4 | |
| SCHEMBL27932154 | 0.74 | TSHR (0.57) | LMNAKCNN4POLBGAACES1 | |
| SCHEMBL1505928 | 0.74 | CYP2C19 (0.52) | CYP2C19AGTR1CYP19A1MEN1KMT2A | |
| SCHEMBL1505948 | 0.74 | AGTR1 (0.49) | CYP2C19AGTR1CYP19A1MEN1KMT2A | |
| SCHEMBL11433215 | 0.73 | KCNN4 (0.47) | CYP19A1MEN1KMT2AMAPTKCNN4 | |
| SCHEMBL6749450 | 0.71 | CYP2C19 (0.52) | CYP2C19AGTR1CYP19A1MEN1KMT2A | |
| SCHEMBL6871299 | 0.71 | CYP19A1 (0.54) | CYP19A1MEN1KMT2ALMNAATM | |
| SCHEMBL6821772 | 0.71 | CES1 (0.50) | CYP19A1MEN1KMT2ALMNAATM | |
| SCHEMBL4800395 | 0.70 | CYP19A1 (0.49) | CYP19A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL812971 | 0.70 | KCNN4 (0.76) | CYP2C19KMT2AMAPTKCNN4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2291378-A2 | N- AND O-SUBSTITUTED 4-Ý2-(DIPHENYLMETHOXY)-ETHYL¨-1-Ý(PHENYL)METHYL¨PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009094428-A2 | N- AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-6995268-B2 | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2005-07-14 | — | — | US | disclosed |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
| WO-2001098266-A2 | N-AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | SLC6A3, SLC6A2, PNMT | CYP2C19 360/4885AGTR1 1814/4885ADRA2A 193/4885 |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | CYP2C19 586/4885AGTR1 1908/4885ADRA2A 227/4885 |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | SLC6A3, SLC6A2, PNMT | CYP2C19 699/4885AGTR1 1376/4885ADRA2A 226/4885 |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | SLC6A3, SLC6A2, PNMT | CYP2C19 542/4885AGTR1 2044/4885ADRA2A 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.